1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Ventas
  6. Summary
    VTR   US92276F1003

VENTAS

(VTR)
  Report
Delayed Nyse  -  04:04 2022-06-29 pm EDT
51.56 USD   +0.88%
06/23Credit Suisse Initiates 24 REIT Stocks, Names 5 Top Picks, Says Inflation Protection to Partially Offset Impact of Rising Rates
MT
06/22BMO Capital Lowers Ventas' Price Target to $57 From $64, Maintains Outperform Rating
MT
06/22Pamela Boneham Joins Ventas Investment Management Platform as Senior Strategic Advisor
BU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/23/2022 06/24/2022 06/27/2022 06/28/2022 06/29/2022 Date
49.94(c) 51.23(c) 51.57(c) 51.11(c) 51.56 Last
1 226 956 2 377 114 1 291 221 1 430 957 1 608 159 Volume
+0.38% +2.58% +0.66% -0.89% +0.88% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 4 175 M - -
Net income 2022 66,9 M - -
Net Debt 2022 12 803 M - -
P/E ratio 2022 299x
Yield 2022 3,50%
Sales 2023 4 503 M - -
Net income 2023 183 M - -
Net Debt 2023 12 025 M - -
P/E ratio 2023 122x
Yield 2023 3,78%
Capitalization 20 608 M 20 608 M -
EV / Sales 2022 8,00x
EV / Sales 2023 7,25x
Nbr of Employees 434
Free-Float 99,5%
More Financials
Company
Ventas, Inc. specializes in owning and managing healthcare and medical-residential facilities. At the end of 2021, the group's portfolio included 1,242 assets consisting of rest homes (821), medical office facilities (313), laboratories and research facilities (43), rehabilitation and long-term acute care facilities (36), skilled nursing facilities (16), medical and surgical facilities (13). Net sales are... 
Sector
Specialized REITs
Calendar
06/30Ex-dividend day for
More about the company
Ratings of Ventas
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A
More Ratings
All news about VENTAS
06/23Credit Suisse Initiates 24 REIT Stocks, Names 5 Top Picks, Says Inflation Protection to..
MT
06/22BMO Capital Lowers Ventas' Price Target to $57 From $64, Maintains Outperform Rating
MT
06/22Pamela Boneham Joins Ventas Investment Management Platform as Senior Strategic Advisor
BU
06/22Ventas, Inc. Appoints Pamela Boneham as Senior Strategic Advisor to Its Ventas Investme..
CI
06/08TRANSCRIPT : Ventas, Inc. Presents at Nareit’s REITweek: 2022 Investor Conference, Ju..
CI
06/06Ventas to Present at Nareit's REITweek 2022 Investor Conference
BU
06/01VENTAS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Even..
AQ
06/01Morgan Stanley Adjusts Ventas' Price Target to $59 from $61.50, Keeps Equalweight Ratin..
MT
05/31Berenberg Bank Adjusts Ventas' Price Target to $60 From $57, Maintains Hold Rating
MT
05/25Ventas Maintains Quarterly Dividend at $0.45 a Share, Payable July 14 to Shareholders a..
MT
05/25Ventas Declares Second Quarter 2022 Dividend of $0.45 per Common Share
BU
05/25Ventas, Inc. Declares Second Quarter 2022 Dividend, Payable on July 14, 2022
CI
05/20RBC Lifts Price Target on Ventas to $63 From $62, Maintains Outperform Rating
MT
05/19Ventas Named a Top Corporate Citizen of 2022 by 3BL Media
BU
05/18Ventas's Outlook Revised by S&P Global Ratings to Stable
BU
More news
News in other languages on VENTAS
06/22Ventas, Inc. nomme Pamela Boneham au poste de conseillère stratégique principale pour s..
05/25Ventas, Inc. Déclare un dividende pour le deuxième trimestre 2022, payable le 14 juille..
05/06Ventas affiche des revenus et des rentrées d'argent normalisés plus élevés au premier t..
05/05Ventas, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
05/05Earnings Flash (VTR) VENTAS affiche un chiffre d'affaires de 1,02 milliard de dollars p..
More news
Analyst Recommendations on VENTAS
More recommendations
Chart VENTAS
Duration : Period :
Ventas Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VENTAS
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 51,56 $
Average target price 63,18 $
Spread / Average Target 22,5%
EPS Revisions
Managers and Directors
Debra A. Cafaro Chairman & Chief Executive Officer
Robert F. Probst Chief Financial Officer & Executive Vice President
Bhavana Devulapally Chief Information Officer & Senior Vice President
Carey S. Roberts EVP, General Counsel, Ethics & Compliance Officer
John D. Cobb Chief Investment Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
VENTAS-0.02%20 428
WELLTOWER INC.-3.03%37 625
HEALTHPEAK PROPERTIES, INC.-29.43%13 743
MEDICAL PROPERTIES TRUST, INC.-33.47%9 344
OMEGA HEALTHCARE INVESTORS, INC.-1.49%6 857
HEALTHCARE TRUST OF AMERICA, INC.-16.59%6 380